The impact of losartan on the lifetime incidence of end-stage renal disease and associated costs: Lifetime projections based on the RENAAL study.

被引：0
|
作者：
Keane, WF
Carides, GW
Shahinfar, S
Dasbach, EJ
Gerth, WC
Alexander, CM
Herman, WH
机构：
[1] Merck & Co Inc, Horsham, PA USA
[2] Univ Michigan, Ann Arbor, MI 48109 USA
来源：
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY | 2002年 / 13卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：264A / 265A
页数：2
相关论文
共 50 条
  • [1] The Impact of Losartan on the Lifetime Incidence of End-Stage Renal Disease and Costs in Patients with Type 2 Diabetes and Nephropathy
    George W. Carides
    Shahnaz Shahinfar
    Erik J. Dasbach
    William F. Keane
    William C. Gerth
    Charles M. Alexander
    William H. Herman
    Barry M. Brenner
    PharmacoEconomics, 2006, 24 : 549 - 558
  • [2] The impact of losartan on the lifetime incidence of end-stage renal disease and costs in patients with type 2 diabetes and nephropathy
    Carides, George W.
    Shahinfar, Shahnaz
    Dasbach, Erik J.
    Keane, William F.
    Gerth, William C.
    Alexander, Charles M.
    Herman, William H.
    Brenner, Barry M.
    PHARMACOECONOMICS, 2006, 24 (06) : 549 - 558
  • [3] Losartan reduces the costs associated with diabetic end-stage renal disease - The RENAAL study economic evaluation
    Herman, WH
    Shahinfar, S
    Carides, GW
    Dasbach, F
    Gerth, WC
    Alexander, CM
    Cook, JR
    Keane, WF
    Brenner, BM
    DIABETES CARE, 2003, 26 (03) : 683 - 687
  • [4] Losartan reduces the costs associated with diabetic end-stage renal disease: The RENAAL study economic evaluation
    Herman, WH
    Shahinfar, S
    Carides, GW
    Dasbach, EJ
    Gerth, WC
    Alexander, CM
    Cook, JR
    Keane, WF
    Brenner, BM
    DIABETES, 2002, 51 : A28 - A28
  • [5] Effect of LDL cholesterol and treatment with losartan on end-stage renal disease in the RENAAL study
    Tershakovec, Andrew M.
    Keane, William F.
    Zhang, Zhongxin
    Lyle, Paulette A.
    Appel, Gerald B.
    McGill, Janet B.
    Parving, Hans-Henrik
    Cooper, Mark E.
    Shahinfar, Shahnaz
    Brenner, Barry M.
    DIABETES CARE, 2008, 31 (03) : 445 - 447
  • [6] Losartan reduces the medical burden and costs associated with End-Stage Renal Disease (ESRD). Implications from the RENAAL Study for Germany.
    Liebl, A
    Carides, GW
    Gerth, WC
    Krobot, KJ
    DIABETOLOGIA, 2002, 45 : A301 - A302
  • [7] The impact of losartan on the lifetime incidence of ESRD and costs in Mexico
    Arredondo, A
    Burke, TA
    Carides, GW
    Lemus, E
    Querol, J
    REVISTA DE INVESTIGACION CLINICA-CLINICAL AND TRANSLATIONAL INVESTIGATION, 2005, 57 (03): : 399 - 405
  • [8] Losartan reduces the costs associated with nephropathy and end-stage renal disease from type 2 diabetes: Economic evaluation of the RENAAL study from a Canadian perspective
    Burgess, ED
    Carides, GW
    Gerth, WC
    Marentette, MA
    Chabot, I
    CANADIAN JOURNAL OF CARDIOLOGY, 2004, 20 (06) : 613 - 618
  • [9] Losartan and anaemia of end-stage renal disease
    Lang, SM
    Schiffl, H
    LANCET, 1998, 352 (9141): : 1708 - 1708
  • [10] Losartan reduces the costs of diabetic end-stage renal disease: An Asian perspective
    Seng, WK
    Hwang, SJ
    Han, DC
    Teong, CC
    Chan, J
    Burke, TA
    Carides, GW
    Choi, YJ
    NEPHROLOGY, 2005, 10 (05) : 520 - 524
12345